NEA 17 fund boosts Korro Bio (KRRO) stake with stock and pre-funded warrants

Rhea-AI Filing Summary

New Enterprise Associates 17, L.P., a 10% owner of Korro Bio, Inc., bought additional securities in the company. On March 10, 2026, it acquired 207,100 shares of Common Stock at $11.11 per share and 242,945 Pre-Funded Warrants at $11.109 per warrant pursuant to a Subscription Agreement dated March 9, 2026.

The Pre-Funded Warrants are exercisable at $0.001 per share at any time after issuance but include a beneficial ownership cap that generally limits the holder to 9.99% of Korro Bio’s outstanding Common Stock, which can be adjusted up to 19.99% with 61 days’ prior notice.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

New Enterprise Associates 17, L.P.

(Last) (First) (Middle)

1954 GREENSPRING DRIVE

SUITE 600

(Street)

TIMONIUM MD 21093

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		P(1)		207,100	A	$11.11	1,297,893	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	$0.001	03/10/2026		P(1)		242,945		(3)	(3)	Common Stock	242,945	$11.109	242,945	D(2)

1. Name and Address of Reporting Person^*

New Enterprise Associates 17, L.P.

(Last) (First) (Middle)

1954 GREENSPRING DRIVE

SUITE 600

(Street)

TIMONIUM MD 21093

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

NEA Partners 17, L.P.

(Last) (First) (Middle)

1954 GREENSPRING DRIVE

SUITE 600

(Street)

TIMONIUM MD 21093

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

NEA 17 GP, LLC

(Last) (First) (Middle)

1954 GREENSPRING DRIVE

SUITE 600

(Street)

TIMONIUM MD 21093

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.

2. The securities are directly held by New Enterprise Associates 17, L.P. ("NEA 17") and are indirectly held by NEA Partners 17, L.P. ("NEA Partners 17"), the sole general partner of NEA 17, NEA 17 GP, LLC ("NEA 17 GP"), the sole general partner of NEA Partners 17, and the individual managers of NEA 17 GP (NEA Partners 17, NEA 17 GP and the individual managers of NEA 17 GP (collectively, the "Managers") together, the "Indirect Reporting Persons"). The Mangers are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony Florence, Jr., Mohamad Makhzoumi, Edward Mathers, Scott Sandell, Paul Walker and Rick Yang. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Indirect Reporting Persons have no pecuniary interest.

3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.

	/s/ Zachary Bambach, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did KRRO’s major holder report on this Form 4?

The filing shows New Enterprise Associates 17, L.P. acquired 207,100 shares of Korro Bio Common Stock and 242,945 Pre-Funded Warrants on March 10, 2026, increasing its economic exposure through both stock and warrant purchases in a single financing transaction.

At what prices did New Enterprise Associates 17, L.P. buy Korro Bio (KRRO) securities?

It acquired Common Stock at about $11.11 per share and Pre-Funded Warrants at about $11.109 per warrant. The warrants are separately exercisable at a nominal $0.001 per share, reflecting a structure similar to purchasing common shares with most value paid upfront.

How many Korro Bio (KRRO) shares and warrants did the insider hold after the transactions?

After the March 10, 2026 transactions, New Enterprise Associates 17, L.P. held 1,297,893 shares of Korro Bio Common Stock and 242,945 Pre-Funded Warrants, according to the reported post-transaction ownership figures in the Form 4 data.

How are the Pre-Funded Warrants for Korro Bio (KRRO) structured for this insider?

The Pre-Funded Warrants are exercisable any time after issuance at an exercise price of $0.001 per share. However, they cannot be exercised if doing so would push the holder’s Common Stock ownership above specified percentage limits stated in the warrant terms.

What ownership limits apply to the Pre-Funded Warrants in the KRRO Form 4 filing?

The warrants generally cap the holder’s Common Stock ownership at 9.99% of outstanding shares after exercise. This cap can be changed at the holder’s option, with 61 days’ prior notice, but cannot exceed 19.99% of Korro Bio’s total Common Stock.

Were Korro Bio (KRRO) securities in this Form 4 bought on the market or directly from the company?

The securities were acquired from Korro Bio pursuant to a Subscription Agreement dated March 9, 2026. This indicates a negotiated financing transaction with the issuer, rather than ordinary open-market purchases on an exchange.